The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07, Zacks reports. Prothena Stock Up 2.1%Shares of PRTA traded up $0.18 during trading hours on Friday, hitting $8.76. Creative Planning now owns 50,569 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 39,879 shares during the period. Wall Street Zen cut Prothena from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates.